GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including the Lung Subtype Platform (LSP) which stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies. GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.